PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

New kind of variable star discovered

Minute variations in brightness reveal whole new class of stars

2013-06-12
(Press-News.org) The Swiss are justly famed for their craftsmanship when creating extremely precise pieces of technology. Now a Swiss team from the Geneva Observatory has achieved extraordinary precision using a comparatively small 1.2-metre telescope for an observing programme stretching over many years. They have discovered a new class of variable stars by measuring minute variations in stellar brightness.

The new results are based on regular measurements of the brightness of more than three thousand stars in the open star cluster NGC 3766 [1] over a period of seven years. They reveal how 36 of the cluster's stars followed an unexpected pattern — they had tiny regular variations in their brightness at the level of 0.1% of the stars' normal brightness. These variations had periods between about two and 20 hours. The stars are somewhat hotter and brighter than the Sun, but otherwise apparently unremarkable. The new class of variable stars is yet to be given a name.

This level of precision in the measurements is twice as good as that achieved by comparable studies from other telescopes — and sufficient to reveal these tiny variations for the first time.

"We have reached this level of sensitivity thanks to the high quality of the observations, combined with a very careful analysis of the data," says Nami Mowlavi, leader of the research team, "but also because we have carried out an extensive observation programme that lasted for seven years. It probably wouldn't have been possible to get so much observing time on a bigger telescope."

Many stars are known as variable or pulsating stars, because their apparent brightness changes over time. How the brightness of these stars changes depends in complex ways on the properties of their interiors. This phenomenon has allowed the development of a whole branch of astrophysics called asteroseismology, where astronomers can "listen" to these stellar vibrations, in order to probe the physical properties of the stars and get to know more about their inner workings.

"The very existence of this new class of variable stars is a challenge to astrophysicists," says Sophie Saesen, another team member. "Current theoretical models predict that their light is not supposed to vary periodically at all, so our current efforts are focused on finding out more about the behaviour of this strange new type of star."

Although the cause of the variability remains unknown, there is a tantalising clue: some of the stars seem to be fast rotators. They spin at speeds that are more than half of their critical velocity, which is the threshold where stars become unstable and throw off material into space.

"In those conditions, the fast spin will have an important impact on their internal properties, but we are not able yet to adequately model their light variations," explains Mowlavi. "We hope our discovery will encourage specialists to address the issue in the hope of understanding the origin of these mysterious variations."



INFORMATION:

Notes

[1] This star cluster is one of several included in this major monitoring programme. NGC 3766 lies about 7000 light-years from Earth in the southern constellation of Centaurus (The Centaur) and is estimated to be about 20 million years old.

More information

This research was presented in a paper "Stellar variability in open clusters I. A new class of variable stars in NGC 3766", by N. Mowlavi et al., published in the journal Astronomy & Astrophysics on 12 June 2013.

The team is composed of N. Mowlavi, F. Barblan, S. Saesen and L. Eyer. All four authors are from the Geneva Observatory in Switzerland.

ESO is the foremost intergovernmental astronomy organisation in Europe and the world's most productive ground-based astronomical observatory by far. It is supported by 15 countries: Austria, Belgium, Brazil, the Czech Republic, Denmark, France, Finland, Germany, Italy, the Netherlands, Portugal, Spain, Sweden, Switzerland and the United Kingdom. ESO carries out an ambitious programme focused on the design, construction and operation of powerful ground-based observing facilities enabling astronomers to make important scientific discoveries. ESO also plays a leading role in promoting and organising cooperation in astronomical research. ESO operates three unique world-class observing sites in Chile: La Silla, Paranal and Chajnantor. At Paranal, ESO operates the Very Large Telescope, the world's most advanced visible-light astronomical observatory and two survey telescopes. VISTA works in the infrared and is the world's largest survey telescope and the VLT Survey Telescope is the largest telescope designed to exclusively survey the skies in visible light. ESO is the European partner of a revolutionary astronomical telescope ALMA, the largest astronomical project in existence. ESO is currently planning the 39-metre European Extremely Large optical/near-infrared Telescope, the E-ELT, which will become "the world's biggest eye on the sky".

Links

Research paper - http://www.eso.org/public/archives/releases/sciencepapers/eso1326/eso1326a.pdf

More information about the Swiss 1.2-metre Leonhard Euler Telescope - http://www.eso.org/public/teles-instr/lasilla/swiss.html

Contacts

Nami Mowlavi
Geneva Observatory, University of Geneva/ISDCSwitzerland
Tel: +41 22 37 92 194
Email: Nami.Mowlavi@unige.ch

Sophie Saesen
Geneva Observatory, University of GenevaSwitzerland
Tel: +41 22 379 24 46
Email: Sophie.Saesen@unige.ch

Richard Hook
ESO Public Information Officer
Garching bei München, Germany
Tel: +49 89 3200 6655
Cell: +49 151 1537 3591
Email: rhook@eso.org



ELSE PRESS RELEASES FROM THIS DATE:

Hands-free talking and texting are unsafe

2013-06-12
SALT LAKE CITY, June 12, 2013 – Using hands-free devices to talk, text or send e-mail while driving is distracting and risky, contrary to what many people believe, says a new University of Utah study issued today by the AAA Foundation for Traffic Safety. "Our research shows that hands-free is not risk-free," says University of Utah psychology Professor David Strayer, lead author of the study, which he conducted for the foundation arm of the nonprofit AAA, formerly known as the American Automobile Association. "These new, speech-based technologies in the car can overload ...

Heroin availability increasing across Washington state

2013-06-12
New data from the University of Washington's Alcohol and Drug Abuse Institute indicates increases in heroin availability, abuse and deaths across the state, particularly among young adults ages 18-29. These increases are concerning because of the high risks of overdose and contracting infectious diseases associated with heroin use. Police drug evidence testing, particularly in 2011 and 2012, points to dramatic increases in heroin. The largest increases were outside of metropolitan areas; the number of pieces of police evidence positive for heroin totaled 842 in 2007 and ...

EULAR 2013 highlights

2013-06-12
Madrid, Spain, 12 June 2013: The launch of the European Rheumatology Research Foundation (ERRF) was today announced at EULAR 2013, the Annual Congress of the European League Against Rheumatism. The European Rheumatology Research Foundation (ERRF) is an independent, non-profit body devoted to promoting research in rheumatic and musculoskeletal diseases (RMDs). The ERRF supports high-quality, peer-reviewed research by raising funds from commercial and non-commercial donors. The ERRF aims to support basic and applied research in order to reduce the burden of disease for ...

Significant improvements in psoriatic arthritis with ustekinumab

2013-06-12
Madrid, Spain, 12 June 2013: New PSUMMIT 2* data first presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, further demonstrate the efficacy of ustekinumab in Psoriatic Arthritis (PsA). Anti-TNF naïve and anti-TNF-experienced patients randomised to one of two ustekinumab doses (45mg or 90mg) demonstrated significant and sustained improvements in the signs and symptoms of PsA, with favourable safety profiles. PsA is a chronic inflammatory arthritis associated with psoriasis which significantly impacts health-related quality of life ...

Patients use OTC NSAIDs even when they have a high risk of serious side effects

2013-06-12
Madrid, Spain, 12 June 2013: A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that one in eight patients at risk of developing a serious adverse drug event (ADE) is taking over-the-counter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs), often to treat a musculoskeletal complaint. Of these high risk OTC NSAID users, over one-third had taken the medication for more than 7 days, and 3% had exceeded the maximum recommended daily dosage. Patients were considered at high risk of a serious ADE from OTC ...

Brodalumab demonstrates significant clinical response in psoriatic arthritis

2013-06-12
Madrid, Spain, 12 June 2013: A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that treatment with brodalumab demonstrates significant clinical response and an acceptable safety profile in subjects with psoriatic arthritis (PsA). PsA is a chronic inflammatory arthritis associated with psoriasis which significantly impacts health-related quality of life in patients, and increases risk of co-morbid cardiovascular and gastrointestinal diseases.2 Psoriasis occurs in 2-3% of the population, with PsA occurring in ...

'Fast track' approach to giant cell arteritis significantly reduces risk of blindness

2013-06-12
Madrid, Spain, 12 June 2013: A new study presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that rapid evaluation for Giant Cell Arteritis (GCA) by Color Doppler Ultrasound (CDUS) followed by immediate initiation of treatment (if required) significantly reduces permanent vision loss. Of the patients evaluated by the ''fast track'' principle from March 2010 to December 2012, 11.1% had transient visual manifestations, and none went on to suffer from permanent visual loss. GCA is a condition in which medium and large-size arteries, ...

CHERISH trial demonstrates efficacy of tocilizumab in juvenile idiopathic arthritis

2013-06-12
Madrid, Spain, 12 June 2013: A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism shows that tocilizumab is efficacious and leads to a sustained clinically meaningful improvement in children with polyarticular Juvenile Idiopathic Arthritis (pcJIA). Tocilizumab is a humanized recombinant antibody, which blocks the receptors where interleukin-6 (IL-6) attaches to the surface of cells. When IL-6 is unable to attach to these cells, they are prevented from driving inflammation. Elevated serum and joint fluid IL-6 levels ...

Abatacept as effective as adalimumab in rheumatoid arthritis

2013-06-12
Madrid, Spain, 12 June 2013: Data from AMPLE presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate comparable efficacy and similar safety profiles between subcutaneous abatacept (ABA) and adalimumab (ADA). AMPLE, the first two-year head-to-head biologics trial, was comprised of 646 biologic-naïve patients with active rheumatoid arthritis (RA) equally randomised to either ABA or ADA, with a stable dose of methotrexate (MTX). 79.2% (252 of 318) ABA patients and 74.7% (245 of 328) ADA patients completed the trial. RA is a ...

Long-term apremilast demonstrates continued efficacy in patients with psoriatic arthritis

2013-06-12
Madrid, Spain, 12 June 2013: New data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism show that apremilast administered to patients with psoriatic arthritis continues to demonstrate meaningful clinical responses beyond 24 weeks. For patients who completed 52 weeks of the study, up to 65% achieved ACR20* response rates. Also, apremilast continued to be well tolerated with an acceptable longer-term safety profile. Apremilast is a novel, oral small-molecule inhibitor of phosphodiesterase 4 (PDE4). It works as an anti-inflammatory ...

LAST 30 PRESS RELEASES:

NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research

Chimpanzee stem cells offer new insights into early embryonic development

This injected protein-like polymer helps tissues heal after a heart attack

FlexTech inaugural issue launches, pioneering interdisciplinary innovation in flexible technology

In Down syndrome mice, 40Hz light and sound improve cognition, neurogenesis, connectivity

Methyl eugenol: potential to inhibit oxidative stress, address related diseases, and its toxicological effects

A vascularized multilayer chip reveals shear stress-induced angiogenesis in diverse fluid conditions

AI helps unravel a cause of Alzheimer's disease and identify a therapeutic candidate

Coalition of Autism Scientists critiques US Department of Health and Human Services Autism Research Initiative

Structure dictates effectiveness, safety in nanomedicine

Mission accomplished for the “T2T” Hong Kong Bauhinia Genome Project

Study identifies how malaria can lead to childhood cancer

An earth-abundant mineral for sustainable spintronics

What makes successful learners? How Minecraft can helps us understand social learning

Researchers create ‘super stem cells’, seeing potential for improved fertility treatment

Empathic comforting varies more within bonobo and chimpanzee species than between them

AACR 2025: Colon cancer risk reduction, predicting melanoma spread and new drug therapies among Ohio State findings

Landmark 20-year screening program drives down colorectal cancer cases, deaths

Can a baby’s DNA predict future disease? This study says it might

Gene mutations linked to worse outcomes in stomach cancer

Blood proteins can predict liver disease up to 16 years before symptoms

Study: New DNA-reading technology holds promise for rare disease research

Study: Antibiotic exposure before age two linked to childhood obesity

Study: Artificial intelligence more accurately identifies child abuse

Study: Opioid use disorder treatment improves pregnancy outcomes

Study: Education improves in-home gun safety

Study: Treatment ineffective for newborns with low oxygen or blood supply

Study: Children with chronic conditions at risk for severe RSV outcomes

Study: Telehealth in pediatric primary care supports judicious antibiotic prescribing

Animal energy usage made visible through video

[Press-News.org] New kind of variable star discovered
Minute variations in brightness reveal whole new class of stars